SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure ...
SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure ...
STOCKHOLM, Sept. 23, 2019 /PRNewswire/ -- Mentice AB (STO: MNTC), a world leader in simulation solutions for endovascular therapies, is teaming with Siemens Healthineers to perform a live LAAC ...
Atrial fibrillation (AF) is a common supraventricular arrhythmia. While anticoagulation is effective in preventing stroke, the risk of major hemorrhage may be increased especially in older patients ...
Percutaneous closure can be described as a less-invasive surgical procedure used to treat patients with atrial septal defect (ASD) or patent foramen ovale (PFO). Since the utilization of percutaneous ...
Watchman trialists combined PREVAIL and PROTECT-AF data in a patient-level meta-analysis. Their conclusions were positive. You will hear that Watchman has now made noninferiority in the late-ischemic ...
NEW ORLEANS — In low-risk patients with atrial fibrillation for whom anticoagulation therapy would be indicated, device-based left atrial appendage closure (LAAC) was about equal to non-vitamin K ...
ORLANDO – November 6, 2021 – SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results